Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Renal Cell Carcinoma Diagnostics
Advertisement
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Video Insights
Conferene Coverage
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on KEYNOTE-564, NEOAVAX, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CREST, ENLIGHTED, and more.
Dr. Brown breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG.
Dr. Brown discusses the latest TAR-200 data from the SunRISe-1 trial in BCG-unresponsive NMIBC, highlighting CR rates.
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.